Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first participant in the RIDD trial – which is testing whether anti-TNF therapy can prevent or slow the progression of Dupuytren’s disease - has received their trial injection. Dupuytren’s disease affects 4% of the general UK population and causes the fingers to curl irreversibly into the palm. There is currently no approved treatment to prevent disease progression.

 The RIDD trial has two parts – our first participant is taking part in the dose response study for patients with advanced disease who are due to have the diseased tissue surgically removed. We will analyse the removed tissue in the lab to see the effect the treatment has had on the cells. The other part of the RIDD trial is for patients with early disease – with nodules in their hand but only mild or no contracture – and this will open in the summer. 

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.